Combinations of cirtuvivint and iadadematat with the PARP1 inhibitor olaparib in five of the PDMR tumor cell lines grown as mct-spheroids resulted in the combination producing sub-additive to additive cytotoxic effects in the 324938-238-R-1 and 565232-114-T-J1 bladder carcinomas and additive to greater-than additive cytotoxicity in the 186277-243-T-J2 and 616215-338-R-J1 colon carcinomas (Figure 6B)[36]. This evidence concerns the gene PARP1 and urinary bladder carcinoma.